875 related articles for article (PubMed ID: 11776302)
21. Comparative pharmacokinetics of LMWHs.
Samama MM; Gerotziafas GT
Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
[TBL] [Abstract][Full Text] [Related]
22. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
23. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
24. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Sarig G; Blumenfeld Z; Leiba R; Lanir N; Brenner B
Thromb Haemost; 2005 Nov; 94(5):980-5. PubMed ID: 16363240
[TBL] [Abstract][Full Text] [Related]
25. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
26. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
27. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
28. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.
Shapiro NL; Kominiarek MA; Nutescu EA; Chevalier AB; Hibbard JU
Pharmacotherapy; 2011 Jul; 31(7):678-85. PubMed ID: 21923455
[TBL] [Abstract][Full Text] [Related]
29. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
Wilson SJ; Wilbur K; Burton E; Anderson DR
Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
[TBL] [Abstract][Full Text] [Related]
30. Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study.
Bai W; Zhang X; Sun S; Wang Q; Li C; Zhang X; Zhao A
BMC Pregnancy Childbirth; 2021 Oct; 21(1):683. PubMed ID: 34620101
[TBL] [Abstract][Full Text] [Related]
31. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Norris LA; Bonnar J; Smith MP; Steer PJ; Savidge G
Thromb Haemost; 2004 Oct; 92(4):791-6. PubMed ID: 15467910
[TBL] [Abstract][Full Text] [Related]
32. [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients].
Janni W; Bergauer F; Rjosk D; Lohscheidt K; Hagena FW
Zentralbl Chir; 2001 Jan; 126(1):32-8. PubMed ID: 11227291
[TBL] [Abstract][Full Text] [Related]
33. Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
Lopez LM
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):56S-61S; discussion 71S-72S. PubMed ID: 11401194
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
35. Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients.
Kuczka K; Baum K; Picard-Willems B; Harder S
Thromb Res; 2009 Nov; 124(5):625-30. PubMed ID: 19625075
[TBL] [Abstract][Full Text] [Related]
36. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism.
Morris TA; Marsh JJ; Konopka R; Pedersen CA; Chiles PG
Thromb Res; 2000 Nov; 100(3):185-94. PubMed ID: 11108906
[TBL] [Abstract][Full Text] [Related]
37. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
[TBL] [Abstract][Full Text] [Related]
38. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
39. Laboratory analysis of blood samples from patients treated with tinzaparin.
Hoppensteadt DA; Willows L; Leitz H; Nicolaides A; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():49-55. PubMed ID: 15085466
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
